Meet Aris Perrou at the AE&T in London and discuss how PAIA Biotech GmbH can help you improve your early #developability screening efforts.👍 Great technology🚀 #antibodydiscovery #mAbs #antibodyengineering #innovation
I'm excited to announce that I'll be attending #Antibody Engineering & Therapeutics Europe 2024, taking place this June in #London. Another great opportunity to discuss #developability with PAIA Biotech GmbH face-to-face and enjoy great talks and poster presentations. Let's meet! 😁
𝗛𝗮𝘃𝗲 𝘆𝗼𝘂 𝗿𝗲𝗴𝗶𝘀𝘁𝗲𝗿𝗲𝗱 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗟𝗮𝗯𝗜𝗡𝗔𝗥 𝗕𝗿𝗲𝗮𝗸 𝘆𝗲𝘁? Time is running out – this event is happening on Thursday! 📅 Date: May 16th, 2024 🕓 Time: 16:00 CEST Reserve your seat for an enlightening first session with Dr. Matthias Gossmann at the LabINAR BREAK, hosted by innoVitro. Discover the transformative strategies in drug discovery using iPSC-cellular models during the webinar “Transforming Drug Discovery: Accelerating Regulatory Acceptance by Integrating Throughput into Microphysiological Systems". What can you expect? ▪️ Case studies highlighting the successful application of these models ▪️ Insights on utilizing cell-based platforms for efficient preclinical drug screening ▪️ An engaging & interactive Q&A sessions with field experts. Will we see you at the webinar? Register today to reserve your spot. Secure your registration: https://ow.ly/JTE950RuB0I #InnovativeDrugDiscovery #Webinar #HighThroughput #iPSCModels #Preclinical #PharmaceuticalDevelopment
Cybin has an exciting journey ahead with multiple key data readouts and clinical milestones expected in the coming months and next year across the pipeline. We look forward to sharing: - Complete Phase 2 CYB003 efficacy and safety data in MDD in Q4 2023 - Phase 1 data for deuterated DMT molecules, CYB004 and SPL028, in Q4 2023 -Additional Phase 2 data assessing 12-week durability for CYB003 in Q1 2024 Cybin CEO Doug Drysdale said, “Looking ahead, Cybin plans to run four clinical studies in 2024, reflecting the team’s strong execution on strategic priorities and commitment to accelerating our programs. We are in an exciting period of clinical development, and we look forward to sharing important data readouts across our pipeline of differentiated therapeutics." Learn more: https://lnkd.in/gk5AXa4u #ChangingMinds #researchanddevelopment #cybin #psychedelicresearch #clinicalresearch #mentalhealthresearch #CybinInc #DrugDevelopment #Biotech #MentalHealth
Don't miss Kim Frederix at today's congress of European Drug Discovery Innovation & Outsourcing Programme organized by Drug Discovery Innovation Programme (DDIP). Schedule a meeting now to discover how InnoSer can help you achieve breakthroughs on your preclinical drug discovery path! InnoSer is active in #DrugDevelopment pipelines, spanning from the early target validation until the late preclinical research phase. Learn more about how you can benefit from our capabilities here: https://lnkd.in/eciRBYbq #DDIP #DDIPEU
7th International Conference on Drug Discovery and Lead Optimization, San Francisco, 1-3 November. Have a chat with Benedetta Montagnini, our Head of Business Development USA & Pacific, and don’t miss her talk: 📅 2nd November at 17:40 💫Power Your Early-Stage Drug Discovery Projects: Innovation in Assays, High-Throughput Screening, Hit-to-Lead and Beyond. Benedetta will give an overview of our early-stage innovative drug discovery services and explain how we can help you advance your project. Stay tuned! #drugdiscovery #leadoptimization #conference
The FDA Modernization Act 2.0 has lifted the requirement for animal testing in drug development, opening the door for advanced technologies like organs-on-chips -- micro-engineered devices that mimic the physiological functions of human organs -- to revolutionize preclinical research. Organs-on-chips promise more accurate, efficient, and human-relevant preclinical drug development, but widespread adoption hinges on further validation and collaboration to set industry-wide standards. Click the link below to learn more. https://lnkd.in/euvggpep #organsonchips #FDAModernizationAct #animaltesting #drugdevelopment Subscribe here to receive our latest insights and newsletters: https://lnkd.in/eGAaapyA
#SwissBiotechDay #AkcesoAdvisors #AndrásIncze Join us at the Swiss Biotech Day next Monday and Tuesday, where our Founder & CEO, Andras Incze, will be serving as a jury member on two pitching sessions! 🎉 The Swiss Biotech Day, hosted by the Swiss Biotech Association, is one of Europe's premier biotechnology conferences, bringing together 2,000 professionals from the global life sciences community. We are very much looking forward to explore how we at Akceso Advisors could help participating biotechs make sure they maximize the value of their asset. This, by helping them reaching target price for the target patient population, thus maximizing net revenue in an ever-more-challenging pharma landscape. See you there! ✍ Find the registration link in the first comment.
Agilent is hosting an Immunotherapy Symposium, followed by a “Live” Demo reception on March 26– in Cambridge from 1pm-6.30pm EST. Seats are limited— register today! Meet industry experts and explore solutions in real-time, impedance-based analysis of cell function, real time metabolism, cell imaging and microscopy, flow cytometers, and more! Learn about our Cell Analysis applications and workflows, get your Software questions answered, and learn how you can get personalized training on YOUR DATA! Heather Sampson Lustig Suzie Shoup Sabrina Hawthorne Jenny (Zhe) Zhang Craig Abrahams Natalia Romero Leyna Z. Diane Kambach, Ph.D. Suzanne Armitstead Melanie Herscovitch Cliff Leavitt Jason Field Daniel Disher Lauren Dostillio Peggy Taphorn Leena Paul, Ph.D #seahorse #immunology #cellandgenetherapy #flowcytometry #metabolism #metabolomics #celltherapymanufacturing #immunooncology #immunotherapy #microscopy #confocal #imaging
Join Agilent's Superhero Seminar to hear how others are activating their biological superpowers. We are thrilled to have a lineup of incredible speakers who are paving the way in the Immunotherapy space, including Hae Lin Jang, PhD from Harvard Medical School and MiJeong Kim, PhD who is a consultant for Pacira Biosciences & Consano Biologics. Be sure to stick around from 5:00PM - 6:30PM for our Drinks & Demos reception where we will toast to your accomplishments. We will have our experts on site conducting software demos and available to answer your most pressing questions. Click here for more information and to save your seat! https://lnkd.in/dzCdXthr
As R&D teams in #Pharma and #BioTech drive innovation with new modalities and personalized medicines, #TechOps face the challenge of removing roadblocks to #Commercialization – production costs and turnaround times. Geoffrey Zassenhaus shares how we helped the CMC team of a leading biotech collaborate to redesign its production processes to reduce costs by a factor of 25 and time to patient by 50%. https://lnkd.in/eDXbbbhf
Gain insights into how master schedule management can revolutionize your research process, accelerating drug development and reducing costs when you read our latest blog post entitled, Optimizing Preclinical Study Timelines with Master Schedule Management. Discover key strategies to streamline preclinical studies and drive efficient timelines. https://hubs.ly/Q02lWxSZ0
Check out our posters illustrating the power of SPR to swiftly drive drug discovery programs forward and yield critical compound binding data! The ability to characterize an interaction can be critical for deciding how to progress a project. These posters demonstrate several of our capabilities at Charnwood Discovery: ➡ SPR assay development for difficult targets ➡ Small molecule screening in multiple different assay formats ➡ Integrated drug discovery between different disciplines and departments #spr #assaydevelopment #drugdiscovery
